Abstract:Abstract High-grade serous ovarian cancer (HGSC) is the most common subtype of ovarian cancer. Most patients with HGSC are diagnosed at advanced stage diseases. Despite the high response rate to platinum/taxane-based chemotherapy, most of these patients will develop recurrent chemoresistant disease. Recent studies showed the cancer associated fibroblasts (CAFs) in the tumor microenvironment (TME) play an important role in modulating the malignant phenotypes of HGSC. CAFs are primarily responsible for producing factors such as cytokines and growth factors to modify the TME niche to promote the malignant phenotypes of cancer cells. Recently, we have identified a previously unrecognized mechanism in which metabolism of reactive CAFs is reprogrammed through an upregulated glutamine anabolic pathway in HGSC. This dysfunctional CAF metabolism confers atypical metabolic flexibility and adaptive mechanisms in CAFs, allowing them to harness carbon and nitrogen from noncanonical sources to synthesize glutamine in nutrient-deprived conditions existing in the TME. Our preliminary data show that tumors developed from syngeneic fallopian epithelial cell-derived cancer cells injected IP into C57BL/6 mice, which started to be fed with normal diet two weeks before tumor cells injection had significantly higher tumor burden than those fed with the glutamine-deprived diet. Moreover, tumor-bearing mice treated with glutaminase inhibitor for 3 weeks demonstrated significantly lower tumor burden than those treated with the control vehicle. These findings suggest that the interplay between CAFs and HGSC cells enriches glutamine in the ovarian TME; and glutamine depletion can not only suppress ovarian tumor growth but also prevent the development of advanced progressive diseases. In addition to the direct promoting effect of glutamine on the glutamine addicted HGSC cells, increased CAF-derived glutamine can also affect the activity of other stromal cell types such as immune cells in the TME, which subsequently modulate HGSC cell growth. Imaging mass cytometry (IMC) and Mass Spectrometry Imaging (MSI) were performed on serial tissue sections of tissue microarrays generated from the abovementioned murine samples. Mice fed with a glutamine-deprived diet or treated with the glutaminase inhibitor not only have a significantly lower tumor burden but also induced dramatic changes in the cellular and molecular composition within the TME. In particular, mice fed with a glutamine-deprived diet had greater B-cell-related immune response, reduced stemness, and EMT of ovarian cancer cells, and more activated CAFs, which may result in increased stiffness of the ECM and subsequently enhance the malignant phenotype of HGSC cells. Further studies to delineate the molecular mechanisms by which spatial cellular and metabolic profiles modulate HGSC pathogenesis and progression are warranted. Citation Format: Sammy Ferri-Borgogno, Kathryn Lu, Basant T. Gamal, Chi Lam Au Yeung, Erin Seeley, Javier A. Gomez, Akshay Basi, Jared K. Burks, Olamide Animasahun, Deepak Nagrath, Samuel C. Mok. The effects of glutamine deprivation on ovarian cancer initiation and progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4779.

Mir-145 Inhibits Glutamine Metabolism Through C-Myc/gls1 Pathways in Ovarian Cancer Cells

Metabolic Shifts Toward Glutamine Regulate Tumor Growth, Invasion and Bioenergetics in Ovarian Cancer

miR‐145 inhibits aerobic glycolysis and cell proliferation of cervical cancer by acting on MYC

New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic

Mir-383 Inhibits Ovarian Cancer Cell Proliferation, Invasion and Aerobic Glycolysis by Targeting LDHA

Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells

miR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells

Mir-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell Through Targeting the Glutaminase [Gls]-Mediated Glutamine Metabolism.

miR-145 inhibits mitochondrial function of ovarian cancer by targeting ARL5B

MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.

Abstract 1208: Glutamine Modulates Cellular NAD+/NADH Homeostasis Thereby Regulating Cancer Metastasis, Drug Sensitivity in Cancer Cells

C-Myc Suppression of Mir-23A/b Enhances Mitochondrial Glutaminase Expression and Glutamine Metabolism.

Abstract 4779: The effects of glutamine deprivation on ovarian cancer initiation and progression

Mir-603 Targeted Hexokinase-2 to Inhibit the Malignancy of Ovarian Cancer Cells.

Abstract 3377: Glutamine Mediated Aggressiveness and Drug Sensitivity in Ovarian Cancer Cells

Glutamine Metabolism Regulators Associated with Cancer Development and the Tumor Microenvironment: A Pan-Cancer Multi-Omics Analysis

Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer

Mir-638 Suppresses Proliferation by Negatively Regulating High Mobility Group A1 in Ovarian Cancer Cells.

MiR-513c Suppresses Neuroblastoma Cell Migration, Invasion, and Proliferation Through Direct Targeting Glutaminase (GLS).

Mitochondrial Mir-181A-5p Promotes Glucose Metabolism Reprogramming in Liver Cancer by Regulating the Electron Transport Chain.

Microrna-133b Targets Glutathione S-Transferase Pi Expression To Increase Ovarian Cancer Cell Sensitivity To Chemotherapy Drugs